Schmallenberg vaccine produced
In a very short timeframe research was able to produce a vaccine and it was demonstrated that vaccinated animals were protected against a challenge with Schmallenberg virus.
The results of several studies were presented as a poster presentation at a satellite symposium on the Schmallenberg virus during the 6th Annual Meeting of EPIZONE (an international network of veterinary research institutes working on epizootic animal diseases), which took place in Brighton (United Kingdom) from June 13-15, 2012.
The vaccine is based on wild-type Schmallenberg virus that has been inactivated and contains an adjuvant that stimulates the immune response. In the studies to date, safety and efficacy has been demonstrated in calves, lambs and pregnant ewes.
“In our studies we looked at the serological response as well as viremia and we have now reported that all vaccinated animals responded with formation of virus neutralizing antibodies. During the trials, all vaccinated animals were protected against Schmallenberg virus infection (complete blockage of viremia), whereas all controls developed viremia after challenge. Moreover, we found a good correlation between antibody titers and viremia”, said Veronique Moulin, research scientist at the virological R&D department at MSD Animal Health.
“Using our experience gained a few years ago during the fast-track development of the first vaccine against bluetongue 8 virus in just 21 months, we are now on track to develop a vaccine against Schmallenberg virus in an even shorter time. After we isolated the virus last December, we have diligently worked in an integrated and interdisciplinary team at BioSciences Center Boxmeer (the Netherlands) and our manufacturing site in Burgwedel (Germany) to develop this vaccine. We anticipate, pending regulatory approvals, to have a vaccine available for our customers by the end of this year”, said Dr. Rene Aerts, vice president Global Biologicals R&D Animal Health.
“Since the emergence of the Schmallenberg virus late summer of 2011, it has spread across several countries in Europe. At this moment it is not possible to predict the course and impact of the endemic in Europe in the near future. We see a potential role for the vaccine in the protection of young breeding stock on infected farms and protection of non-infected farms in risk areas" said Dr. Aerts.
No comments posted yet. Be the first to post a comment
Please enter your name
Please enter your comment
Your comment submitted successfully.Please wait for admin approval.
Some error on your process.Please try one more time.
The permanent eradication of Bovine Viral Diarrhoea [BVD] in Scottish cattl...
The abolition of milk quotas in Europe on 1st April has resulted in a numbe...
The top 14 milk producing countries in Europe will increase their productio...
Matt Ware is the NFU's head of government and parliamentary affairs, based ...
There is a 'desperate need' to improve farmgate returns given low incomes a...
Rapid stem extension, after a slow start to spring, is likely to create spl...
The time has come for landlords to expect to see reductions in farm rents, ...
Cogent’s reputation as a source of the highest calibre sires has been enhan...
The spread of exotic and aggressive strains of a plant fungus is presenting...